On February 14, 2025, the US Food and Drug Administration approved vimseltinib for patients with symptomatic tenosynovial giant cell tumor not amenable to surgical resection.
On February 14, 2025, the US Food and Drug Administration approved vimseltinib for patients with symptomatic tenosynovial giant cell tumor not amenable to surgical resection.
On February 14, 2025, the US...